Recombinant osteoprotegerin - Amgen

Drug Profile

Recombinant osteoprotegerin - Amgen

Alternative Names: AMGN-0007; OCIF - Amgen; OPG - Amgen; Osteoclastogenesis Inhibiting Factor - Amgen

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Class
  • Mechanism of Action Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Hyperparathyroidism
  • Discontinued Bone disorders; Cancer pain; Postmenopausal osteoporosis; Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hyperparathyroidism in USA
  • 15 Sep 2009 Preclinical trials in Hyperparathyroidism in USA (unspecified route)
  • 15 Sep 2009 Pharmacodynamics data from a preclinical trial in Hyperparathyroidism presented at the 31st Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top